Methotrexate Treatment in Cases of Ectopic Pregnancy With Relative Contraindications
NCT ID: NCT07186127
Last Updated: 2025-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
230 participants
OBSERVATIONAL
2025-05-01
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Purpose:
The aim of this study is to evaluate the effectiveness and safety of methotrexate treatment in women with ectopic pregnancy who belong to a group for whom this treatment is relatively contraindicated.
Background:
Methotrexate is a medication commonly used in the treatment of ectopic pregnancy (a pregnancy that occurs outside the uterus, usually in the fallopian tube). However, in certain conditions - such as kidney or liver dysfunction - methotrexate use may carry increased risks. These situations are known as relative contraindications. This study will retrospectively examine treatment outcomes in this specific patient population.
Method:
The study will analyze medical records of patients who were previously treated with methotrexate for ectopic pregnancy. No new interventions will be performed. The analysis will be based solely on existing clinical data.
Why Is This Important? The findings of this study may help us better understand the safety limits of methotrexate therapy and guide healthcare providers in managing similar cases in the future.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy
NCT06554470
Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy
NCT06426979
The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy
NCT02714998
Treatment of Ectopic Pregnancy by Low Dose of Methotrexate
NCT06300333
Evaluation of Therapeutic Strategies for Treatment of Ectopic Pregnancies (EP) and Evaluation of Subsequent Fertility
NCT00137982
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the literature, data on the use of methotrexate in patients with relative contraindications are limited, and findings regarding treatment response, the rate of transition to surgery, and complications in this patient group remain unclear. This lack of clarity can lead to uncertainty in clinical decision-making.
In this study, the retrospective data of 238 patients diagnosed with ectopic pregnancy and treated with methotrexate at our institution, a training and research hospital, between 2019 and 2024 will be analyzed. The number of patients with relative contraindications and the criteria by which they were deemed eligible for methotrexate treatment will be determined during the analysis phase.
This retrospective observational study aims to identify the factors affecting treatment success, particularly in the group of patients with relative contraindications, thereby contributing to patient selection and management processes. By providing real-world data on current clinical practice, this research may also serve as a foundation for future prospective studies.
Purpose of the Study The aim of this study is to retrospectively examine the clinical data of patients who were treated with methotrexate for ectopic pregnancy at a training and research hospital between 2019 and 2024, in order to evaluate treatment response rates and the factors affecting treatment success. In particular, by analyzing the effectiveness of methotrexate therapy in patients with relative contraindications, the rate of transition to surgical intervention, and complications arising during treatment, the study aims to more clearly determine the suitability of medical treatment for this patient group.
The hypothesis of the research is that methotrexate treatment may be effective and safe in ectopic pregnancy cases that meet appropriate criteria, even in the presence of relative contraindications. In addition, certain clinical and laboratory parameters-such as initial beta-human chorionic gonadotropin (β-hCG) levels, mass size, and the presence of fluid in the recto uterine pouch (Douglas pouch)-are anticipated to play a significant role in predicting treatment success.
Study Protocol Plan Ethics approval for this study was obtained on May 15, 2025. This study is a retrospective, descriptive, and observational analysis conducted at a training and research hospital, evaluating the data of patients who received methotrexate treatment for ectopic pregnancy between 2019 and 2024. Clinical data of a total of 236 ectopic pregnancy cases treated with methotrexate will be assessed by reviewing the hospital information management system and patient records.
The study will include both patients who responded to methotrexate treatment and those who did not benefit from it and required surgical intervention. Detailed evaluations will be conducted on each patient's demographic characteristics, obstetric history, mode of delivery, history of previous ectopic pregnancy, methotrexate dosage and administration method, revision curettage procedures performed during treatment, laboratory findings such as complete blood count (CBC) and beta-human chorionic gonadotropin (β-hCG), ultrasound findings including the identified ectopic focus and the presence of free fluid in the recto uterine pouch (Douglas pouch), treatment duration, length of hospital stay, need for surgical intervention, time taken for β-hCG levels to become negative, and pre- and postoperative β-hCG levels in surgical cases.
Response to methotrexate treatment will be defined as observing the expected decline in β-hCG levels over time and the completion of the process without the need for surgical intervention. Characteristics of patients who did not respond to treatment and required surgery will be analyzed separately to identify potential predictors of treatment failure. Data will be analyzed using Statistical Package for the Social Sciences (SPSS), and in addition to descriptive statistics, significance tests will be applied to evaluate the relationship between various parameters and treatment success.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1 and group 2
Group 1 with indication for MTX treatment and group 2 with relative indication for MTX treatment
Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond
MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond
MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received methotrexate (MTX) treatment
* Underwent surgical treatment due to lack of response to MTX therapy
* Compliant with treatment follow-up
Exclusion Criteria
* Participants non-compliant with follow-up
18 Years
48 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bagcilar Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
gülhan özüm, md
Role: PRINCIPAL_INVESTIGATOR
Sağlık Bilimleri Üniversitesi, Bağcılar Eğitim ve Araştırma Hastanesi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Health Sciences, Training and Research Hospital
Istanbul, Türkiye, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Cohen A, Bar-On S, Cohen Y, Sandel O, Fouks Y, Michaan N, Tzur T, Levin I. Ruptured ectopic pregnancies following methotrexate treatment: clinical course and predictors for improving patient counseling. Reprod Sci. 2022 Apr;29(4):1209-1214. doi: 10.1007/s43032-022-00881-7. Epub 2022 Feb 14.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025/05/01/044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.